plusbiome AG is pioneering a new class of anticancer medicines to deliver superior therapy outcomes compared to current treatment options.
Our therapeutic ambition is to regulate selectively microbiome-mediated mechanisms to drive effective anti-cancer immunity.
Products, services, technology
We provide access to our extensive expertise on the gut microbiome.
Cooperation possibilities
By focusing on the immune conditioning of the microbiome in cancer therapies we develop our portfolio of assets, which we are validating in pre-clinical studies. Reach out if you're interested in microbiome-mediated mechanisms of disease or are interested in licensing relevant enabling technologies.
- http://www.plusbiome.com
- info@plusbiome.com
- Julia Biwer
Some insights
There is no disease that is not linked to the microbiome. We enable new life-saving therapies that leverage on the knowledge of how the microbiome influences our health.